BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 32733352)

  • 1. Longitudinal Monitoring of Parkinson's Disease in Different Ethnic Cohorts: The DodoNA and LONG-PD Study.
    Markopoulou K; Aasly J; Chung SJ; Dardiotis E; Wirdefeldt K; Premkumar AP; Schoneburg B; Kartha N; Wilk G; Wei J; Simon KC; Tideman S; Epshteyn A; Hadsell B; Garduno L; Pham A; Frigerio R; Maraganore D
    Front Neurol; 2020; 11():548. PubMed ID: 32733352
    [No Abstract]   [Full Text] [Related]  

  • 2. Multifactorial assessment of Parkinson's disease course and outcomes using trajectory modeling in a multiethnic, multisite cohort - extension of the LONG-PD study.
    Chase BA; Krueger R; Pavelka L; Chung SJ; Aasly J; Dardiotis E; Premkumar AP; Schoneburg B; Kartha N; Aunaetitrakul N; Frigerio R; Maraganore D; Markopoulou K
    Front Aging Neurosci; 2023; 15():1240971. PubMed ID: 37842125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does the MDS-UPDRS provide the precision to assess progression in early Parkinson's disease? Learnings from the Parkinson's progression marker initiative cohort.
    Regnault A; Boroojerdi B; Meunier J; Bani M; Morel T; Cano S
    J Neurol; 2019 Aug; 266(8):1927-1936. PubMed ID: 31073716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics and influencing factors of
    Kangli F; Hongguang Z; Yinghua L; Xiaoxiao D; Yuyin D; Lulu G; Yi L; Zhihui S; Ying Z
    Front Neurol; 2023; 14():1195577. PubMed ID: 37483437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum Uric Acid in LRRK2 Related Parkinson's Disease: Longitudinal Data from the PPMI Study.
    Bougea A; Koros C; Papagiannakis N; Simitsi AM; Prentakis A; Papadimitriou D; Pachi I; Antonelou R; Angelopoulou E; Beratis I; Bozi M; Papageorgiou SG; Trapali XG; Stamelou M; Stefanis L
    J Parkinsons Dis; 2021; 11(2):633-640. PubMed ID: 33682725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data.
    Pagano G; Boess FG; Taylor KI; Ricci B; Mollenhauer B; Poewe W; Boulay A; Anzures-Cabrera J; Vogt A; Marchesi M; Post A; Nikolcheva T; Kinney GG; Zago WM; Ness DK; Svoboda H; Britschgi M; Ostrowitzki S; Simuni T; Marek K; Koller M; Sevigny J; Doody R; Fontoura P; Umbricht D; Bonni A; ;
    Front Neurol; 2021; 12():705407. PubMed ID: 34659081
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical features and relative factors of constipation in a cohort of Chinese patients with Parkinson's disease.
    Sun BH; Wang T; Li NY; Wu Q; Qiao J
    World J Gastrointest Pharmacol Ther; 2021 Jan; 12(1):21-31. PubMed ID: 33564494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Study on the Clinical Features of Parkinson's Disease With Probable Rapid Eye Movement Sleep Behavior Disorder.
    Long K; Wan C; Xiang Y; Liu J; Xu Q; Sun Q; Wang Z; Tian Y; Fang L; Yang Y; Yan X; Tang B; Guo J
    Front Neurol; 2020; 11():979. PubMed ID: 33041969
    [No Abstract]   [Full Text] [Related]  

  • 9. Longitudinal Change and Progression Indicators Using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale in Two Independent Cohorts with Early Parkinson's Disease.
    Bartl M; Dakna M; Schade S; Wicke T; Lang E; Ebentheuer J; Weber S; Trenkwalder C; Mollenhauer B
    J Parkinsons Dis; 2022; 12(1):437-452. PubMed ID: 34719511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolution of prodromal parkinsonian features in a cohort of
    Avenali M; Toffoli M; Mullin S; McNeil A; Hughes DA; Mehta A; Blandini F; Schapira AHV
    J Neurol Neurosurg Psychiatry; 2019 Oct; 90(10):1091-1097. PubMed ID: 31221723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of integrity and atrophy in cingulate structural covariance networks in Parkinson's disease.
    de Schipper LJ; van der Grond J; Marinus J; Henselmans JML; van Hilten JJ
    Neuroimage Clin; 2017; 15():587-593. PubMed ID: 28652971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Motor subtypes and other risk factors associated with drooling in Parkinson's disease patients.
    Mao CJ; Xiong YT; Wang F; Yang YP; Yuan W; Zhu C; Chen J; Liu CF
    Acta Neurol Scand; 2018 May; 137(5):509-514. PubMed ID: 29315470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Motor subtypes and clinical characteristics in sporadic and genetic Parkinson's disease groups: analysis of the PPMI cohort.
    Jeong EH; Lee JY; Han SK; Song YS
    Front Neurol; 2023; 14():1276251. PubMed ID: 37954645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of depression and anxiety via patient-assessed tremor severity, not physician-reported motor symptom severity, in patients with Parkinson's disease or essential tremor who have undergone deep brain stimulation.
    Achey RL; Yamamoto E; Sexton D; Hammer C; Lee BS; Butler RS; Thompson NR; Nagel SJ; Machado AG; Lobel DA
    J Neurosurg; 2018 Dec; 129(6):1562-1571. PubMed ID: 29473781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of GBA Mutations and the E326K Polymorphism With Motor and Cognitive Progression in Parkinson Disease.
    Davis MY; Johnson CO; Leverenz JB; Weintraub D; Trojanowski JQ; Chen-Plotkin A; Van Deerlin VM; Quinn JF; Chung KA; Peterson-Hiller AL; Rosenthal LS; Dawson TM; Albert MS; Goldman JG; Stebbins GT; Bernard B; Wszolek ZK; Ross OA; Dickson DW; Eidelberg D; Mattis PJ; Niethammer M; Yearout D; Hu SC; Cholerton BA; Smith M; Mata IF; Montine TJ; Edwards KL; Zabetian CP
    JAMA Neurol; 2016 Oct; 73(10):1217-1224. PubMed ID: 27571329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of sleep-related symptoms on clinical motor subtypes and disability in Parkinson's disease: a multicentre cross-sectional study.
    Suzuki K; Okuma Y; Uchiyama T; Miyamoto M; Sakakibara R; Shimo Y; Hattori N; Kuwabara S; Yamamoto T; Kaji Y; Hirano S; Kadowaki T; Hirata K;
    J Neurol Neurosurg Psychiatry; 2017 Nov; 88(11):953-959. PubMed ID: 28847794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The clinical efficacy of the stratification medical treatment based on the risk estimation of motor complications in Parkinson's disease].
    Wan Y; Xiao RQ; Zhao JH; Zhang Y; Gan J; Wu N; Song L; Li L; Qi C; Chen W; Wang XJ; Liu ZG
    Zhonghua Yi Xue Za Zhi; 2022 Feb; 102(7):491-498. PubMed ID: 35184502
    [No Abstract]   [Full Text] [Related]  

  • 18. Predicting Depression in Parkinson's Disease Using Commonly Available PD Questionnaires.
    Camerucci E; Lyons KE; Pahwa R
    J Clin Med; 2024 Apr; 13(7):. PubMed ID: 38610834
    [No Abstract]   [Full Text] [Related]  

  • 19. 18F-FP-CIT Positron Emission Tomography for Correlating Motor and Cognitive Symptoms of Parkinson's Disease.
    Yang Y; Cheon M; Kwak YT
    Dement Neurocogn Disord; 2017 Sep; 16(3):57-63. PubMed ID: 30906372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Constructing Prediction Models for Freezing of Gait by Nomogram and Machine Learning: A Longitudinal Study.
    Xu K; Zhou XX; He RC; Zhou Z; Liu ZH; Xu Q; Sun QY; Yan XX; Wu XY; Guo JF; Tang BS
    Front Neurol; 2021; 12():684044. PubMed ID: 34938251
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.